MicroRNA-1294 inhibited oral squamous cell carcinoma growth by targeting c-Myc

Wang,Zuojun; Yan,Jinsheng; Zou,Tingqian; Gao,Hui

doi:10.3892/ol.2018.8967

MicroRNA-1294 inhibited oral squamous cell carcinoma growth by targeting c-Myc

Authors:
- Zuojun Wang
- Jinsheng Yan
- Tingqian Zou
- Hui Gao
View Affiliations

Affiliations: Department of Stomatology, Stomatological Hospital of Jingmen City, Jingmen, Hubei 448000, P.R. China, School of Traditional Chinese Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China, Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: June 13, 2018 https://doi.org/10.3892/ol.2018.8967
Pages: 2243-2250
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral squamous cell carcinoma (OSCC) is the predominant histological type of oral cancer. The 5-year survival rate of OSCC is only ~50%. c-Myc is a known oncogene and target gene in various cancer types, including OSCC. The presnet study revealed that c-Myc is one of the target genes of miR-1294. Results indicated lower levels of miR-1294 in OSCC tissues samples collected from 24 patients with OSCC. Notably, overexpression of miR-1294 inhibited proliferation and migration in OSCC cell lines and inhibition of miR-1294 promoted cell growth and migration in OSCC cell lines. Moreover, miR-1294 can target the 3'UTR of c-Myc, as we identified a negative correlation between c-Myc mRNA expression and miR-1294 expression in 24 OSCC tissues. In conclusion, the data demonstrate the tumor suppressive role of miR-1294 in OSCC.

View Figures

View References

1	Rivera C: Essentials of oral cancer. Int J Clin Exp Pathol. 8:11884–11894. 2015.PubMed/NCBI
2	Gupta PC: Mouth cancer in India: A new epidemic? J Indian Med Assoc. 97:370–373. 1999.PubMed/NCBI
3	Mehrotra R, Singh M, Kumar D, Pandey A, Gupta R and Sinha U: Age specific incidence rate and pathological spectrum of oral cancer in Allahabad. Indian J Med Sci. 57:400–404. 2003.PubMed/NCBI
4	Zheng CM, Ge MH, Zhang SS, Tan Z, Wang P, Zheng RS, Chen WQ and Xia QM: Oral cavity cancer incidence and mortality in China, 2010. J Cancer Res Ther. 11 Suppl 2:C149–C154. 2015. View Article : Google Scholar : PubMed/NCBI
5	Lingen MW, Kalmar JR, Karrison T and Speight PM: Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 44:10–22. 2008. View Article : Google Scholar : PubMed/NCBI
6	Ries L, Eisner M, Kosary C, et al: Cancer statistics review, 1975–2002. Bethesda, MD: National Cancer Institute 21; 2005
7	Little CD, Nau MM, Carney DN, Gazdar AF and Minna JD: Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 306:194–196. 1983. View Article : Google Scholar : PubMed/NCBI
8	Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
9	Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dubik D, Dembinski TC and Shiu RP: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res. 47:6517–6521. 1987.PubMed/NCBI
11	Chen CR, Kang Y and Massagué J: Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA. 98:992–999. 2001. View Article : Google Scholar : PubMed/NCBI
12	Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J and Callahan R: Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA. 83:4834–4838. 1986. View Article : Google Scholar : PubMed/NCBI
13	Peng SY, Lai PL and Hsu HC: Amplification of the c-myc gene in human hepatocellular carcinoma: Biologic significance. J Formos Med Assoc. 92:866–870. 1993.PubMed/NCBI
14	Hsu T, Möröy T, Etiemble J, Louise A, Trépo C, Tiollais P and Buendia MA: Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell. 55:627–635. 1988. View Article : Google Scholar : PubMed/NCBI
15	Pai R, Pai S, Lalitha R, Kumaraswamy S, Lalitha N, Johnston R and Bhargava M: Over-expression of c-Myc oncoprotein in oral squamous cell carcinoma in the South Indian population. Ecancermedicalscience. 3:1282009. View Article : Google Scholar : PubMed/NCBI
16	Chen YJ, Lin SC, Kao T, Chang CS, Hong PS, Shieh TM and Chang KW: Genome-wide profiling of oral squamous cell carcinoma. J Pathol. 204:326–332. 2004. View Article : Google Scholar : PubMed/NCBI
17	Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS and Chen C: Real-time PCR quantification of precursor and mature microRNA. Methods. 44:31–38. 2008. View Article : Google Scholar : PubMed/NCBI
18	Liu K, Li L, Rusidanmu A, Wang Y and Lv X: Down-regulation of miR-1294 is related to dismal prognosis of patients with esophageal squamous cell carcinoma through elevating c-Myc expression. Cell Physiol Biochem. 36:100–110. 2015. View Article : Google Scholar : PubMed/NCBI
19	Bustin SA: Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): TRends and problems. J Mol Endocrinol. 29:23–39. 2002. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Ren X, Zhang Z, Tian J, Wang H, Song G, Guo Q, Tian J, Han Y, Liao Q, Liu G, et al: The downregulation of c-Myc and its target gene hTERT is associated with the antiproliferative effects of baicalin on HL-60 cells. Oncol Lett. 14:6833–6840. 2017.PubMed/NCBI
22	Gerlier D and Thomasset N: Use of MTT colorimetric assay to measure cell activation. J Immunol Methods. 94:57–63. 1986. View Article : Google Scholar : PubMed/NCBI
23	Fotakis G and Timbrell JA: In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett. 160:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
24	Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56:279–285. 1987. View Article : Google Scholar : PubMed/NCBI
25	Ferrari M, Fornasiero MC and Isetta AM: MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods. 131:165–172. 1990. View Article : Google Scholar : PubMed/NCBI
26	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
27	Field J: Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur J Cancer B Oral Oncol. 28:67–76. 1992. View Article : Google Scholar
28	Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI and Moore JP: Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene. 4:1463–1468. 1989.PubMed/NCBI
29	de Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G, Lerman A, Lerman LO and Napoli C: c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle. 2:325–328. 2003. View Article : Google Scholar : PubMed/NCBI
30	Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 19:1–11. 1999. View Article : Google Scholar : PubMed/NCBI
31	Takeda K, Kaisho T and Akira S: Toll-like receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar : PubMed/NCBI
32	Moresco EM, LaVine D and Beutler B: Toll-like receptors. Curr Biol. 21:R488–R493. 2011. View Article : Google Scholar : PubMed/NCBI
33	Akira S, Takeda K and Kaisho T: Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol. 2:675–680. 2001. View Article : Google Scholar : PubMed/NCBI
34	Fig TLR: Toll-like receptors. 2017.
35	Aderem A and Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature. 406:782–787. 2000. View Article : Google Scholar : PubMed/NCBI
36	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
37	Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol. 17:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
38	Kawai T and Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 34:637–650. 2011. View Article : Google Scholar : PubMed/NCBI
39	Mäkinen LK, Ahmed A, Hagström J, Lehtonen S, Mäkitie AA, Salo T, Haglund C and Atula T: Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. J Oral Pathol Med. 45:338–345. 2016. View Article : Google Scholar : PubMed/NCBI
40	Sutmuller RP, den Brok MH, Kramer M, Bennink EJ, Toonen LW, Kullberg BJ, Joosten LA, Akira S, Netea MG and Adema GJ: Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest. 116:485–494. 2006. View Article : Google Scholar : PubMed/NCBI